Adverse event development in clinical oncology trials

[...]one minus the Kaplan-Meier estimator of the probability of the occurrence of a specific adverse event overestimates the true adverse events probability. A correct quantification of the absolute adverse events risk over time also represents an important prerequisite for a meaningful benefit-risk assessment of treatments in drug approval and reimbursement decision making.